An Act Concerning Minors Experiencing Gender Dysphoria Or Incongruence.
Summary
HB 6609 would amend Connecticut’s general statutes to restrict certain gender-affirming medical treatments for minors under 18. Specifically, it would prohibit prescribing puberty-blocking drugs and artificial cross-sex hormones for uses not approved by the federal Food and Drug Administration, including treatment for gender dysphoria or incongruence. It would also prohibit surgical intervention for minors for sex reassignment or treatment of gender dysphoria or incongruence.
In addition to the prohibitions, the bill directs that psychotherapy be promoted for minors experiencing stress related to gender dysphoria or incongruence. The stated purpose is to ensure that the best interests of minors are protected in these circumstances.
Impact
If enacted, the bill would significantly alter state law governing medical treatment for minors by limiting access to puberty blockers, cross-sex hormones, and gender-affirming surgeries when used to treat gender dysphoria or incongruence. It would affect physicians, surgeons, mental health providers, minors, and their families, and would likely create new compliance obligations for medical professionals and institutions. The bill also references FDA-approved uses, which could narrow permissible prescribing practices for certain medications.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the available context does not show a documented legislative debate or recorded support/opposition. The bill’s framing suggests a protective rationale centered on minors’ welfare, while its policy direction is consistent with a restrictive approach to gender-affirming care for youth. Because no transcripts or vote history are provided, the broader sentiment in committee cannot be determined from the record supplied.
Contention
The main point of contention is likely the bill’s restriction on gender-affirming medical care for minors, especially the prohibition on puberty blockers, cross-sex hormones, and surgical treatment for gender dysphoria or incongruence. Supporters would likely emphasize child protection, informed consent, and caution around irreversible treatment, while opponents would likely argue that the bill interferes with medically accepted care, parental decision-making, and access to treatment for transgender and gender-diverse youth. The bill’s reliance on FDA-approved uses may also raise questions about how broadly the restrictions would apply in practice.